<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04407078</url>
  </required_header>
  <id_info>
    <org_study_id>AJIRB-MED-OBS-18-273</org_study_id>
    <nct_id>NCT04407078</nct_id>
  </id_info>
  <brief_title>Sugammadex on Remifentanil Ce for Preventing Emergence Cough in Female</brief_title>
  <official_title>Department of Anesthesiology and Pain Medicine, Ajou University School of Medicine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ajou University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ajou University School of Medicine</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the optimal Ce of remifentanil for preventing
      emergence cough following extubation during general anesthesia in female who are reversed
      with sugammadex or neostigmine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Remifentanil is a potent ultrashort-acting opioid, with rapid onset and offset of drug
      effect. It allows rapid anesthetic emergence even after a prolonged infusion, and decreases
      the at-risk time during extubation. In addition, cough suppression of remifentanil enables
      smooth extubation with reduced complications. However, the infusion of remifentanil
      suppresses the emergence cough effectively in clinical practice, whereas it still delays the
      awakening from anesthesia, resulting in prolonged emergence time. Reduced Ce of remifentanil
      during emergence would decrease the adverse events that are associated with remifentanil
      infusion.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>optimal Ce of remifentanil</measure>
    <time_frame>from the ene of surgery until endotracheal extubation</time_frame>
    <description>Using Dixon methods, evaluating of optimal Ce of remifentanil for preventing emergence cough following extubation during general anesthesia</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Gallbladder Diseases</condition>
  <arm_group>
    <arm_group_label>Sugammadex group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sugammadex group receives the intravenous sugammadex of 2 mg/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neostigmine group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Neostigmine group receives the intravenous neostigmine 50 ug/kg and glycopyrrolate 10 ug/kg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex Injectable Product</intervention_name>
    <description>Sugammadex of 2 mg/kg is injected.</description>
    <arm_group_label>Sugammadex group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neostigmine Injectable Product</intervention_name>
    <description>Neostigmine of 50 ug/kg and Glycopyrrolate of 10 ug/kg are injected.</description>
    <arm_group_label>Neostigmine group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Laparoscopic cholecystectomy under general anesthesia

        Exclusion Criteria:

          -  BMI &gt; 30 kg/m2, respiratory infection, uncontrolled hypertension
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Anesthesiology and Pain Medicine, Ajou University School of Medicine</name>
      <address>
        <city>Suwon</city>
        <state>Gyeonggido</state>
        <zip>16499</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ji Eun Kim</last_name>
      <phone>82-31-219-5575</phone>
      <email>beye98@aumc.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 25, 2020</study_first_submitted>
  <study_first_submitted_qc>May 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 29, 2020</study_first_posted>
  <last_update_submitted>May 25, 2020</last_update_submitted>
  <last_update_submitted_qc>May 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ajou University School of Medicine</investigator_affiliation>
    <investigator_full_name>Ji Eun Kim</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gallbladder Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neostigmine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

